Skip to content

InPen Smart Insulin System Novo - GreyRecalls & reported problems

Companion Medical, Inc. · The InPen is a home-use reusable pen injector for single-patient use by people with diabetes under the supervision of an adult caregiver, or by a patient age 7 and older for the self-injection of a desired dose of insulin. The pen injector is compatible with Lilly Humalog® U-100 3.0 mL cartridges, Novo Nordisk Novolog® U-100 3.0 mL cartridges, and Novo Nordisk Fiasp® U-100 3.0 mL cartridges and single-use detachable and disposable pen needles (not included). The pen injector allows the user to dial the desired dose from 0.5 to 30 units in one-half (1/2) unit increments. The InPen dose calculator, a component of the InPen app, is indicated for the management of diabetes by people with diabetes under the supervision of an adult caregiver, or by a patient age 7 and older for calculating an insulin dose or carbohydrate intake based on user entered data. For an insulin dose based on amount of carbohydrates, a healthcare professional must provide patient-specific target blood glucose, insulin-to-carbohydrate ratio, and insulin sensitivity parameters to be programmed into the software prior to use. For an insulin dose based on fixed/variable meal sizes, a healthcare professional must provide patient-specific fixed doses/meal sizes to be programmed into the software prior to use. · Class 2

Data updated Oct 18, 2026 from official FDA records · Editorial policy

1 open recall names this device. See the recall details and contact the manufacturer or your healthcare provider.

Adverse event reports
1
Deaths reported
0
Injuries reported
0
Recalls naming it
1

Summary

The FDA's MAUDE database contains 1 adverse event report that list this exact device (DI 10862088000351), received between Jun 12, 2020 and Jun 12, 2020 — classified as 1 malfunction.

The most frequently reported specific device problem is “Wireless Communication Problem” (1 report).

1 FDA recall record name this device's identifier, 1 still open.

Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 18, 2026.

Recalls naming this device

  1. Nov 8, 2022Class IIOpen, Classified

    Diabetes management app may crash immediately upon opening, while using the app and/or while app is running in the background, which may lead to inability to use the app. An error message may be displayed indicating the app has stopped or isn't responding. After the crash, a present dose reminder is not displayed, which may lead to delayed insulin therapy and potentially resulting in hyperglycemia.

    Z-0741-2023 · Root cause: Software design · Recall details · FDA record ↗

Most reported problems

Device problems

  • Wireless Communication Problem1

Patient problems

  • No Consequences Or Impact To Patient1

Recent adverse event reports

The 1 most recent of 1 reports, in the reporter's own words as published by the FDA.

  • MalfunctionJun 12, 2020Wireless Communication Problem; Wireless Communication Problem

    IT WAS REPORTED THAT A BOLUS DID NOT DISPLAY ON THE INPEN APPLICATION. CONSEQUENTLY, THE PATIENT REPEATED THE DOSE. PATIENT WAS UNINJURED AND NO MEDICAL CARE WAS NEEDED. BLOOD GLUCOSE VALUES COULD NOT BE PROVIDED BY THE PATIENT. COMPANION MEDICAL RECEIVED THE PRODUCT FOR INVESTIGATION. THE RETURNED PEN MET MECHANICAL DESIGN SPECIFICATIONS AND THE USER EXPERIENCE COULD NOT BE DUPLICATED. CLOUD DATA WAS REVIEWED AND POOR BLUETOOTH LATENCY ON (B)(6) 2020 WAS CONFIRMED. THE MOST LIKELY ROOT CAUSE WAS DETERMINED TO BE POOR BLUETOOTH LATENCY. THE CUSTOMER COMPLAINT OF A BOLUS NOT DISPLAYING ON THE APP WAS CONFIRMED VIA DATA.

    Patient problems: No Consequences Or Impact To Patient

    MAUDE report 10150846 ↗

Other Syringe, Piston devices

All Syringe, Piston devices →

Sources and updates

How reports and recalls are matched · Editorial policy · Report an error on this page